{"name":"GlycoNex, Inc.","slug":"glyconex-inc","ticker":"","exchange":"","domain":"","description":"GlycoNex, Inc. is a biotechnology company focused on the development of novel therapeutics targeting glycosylation pathways. The company's lead candidate, GNX102, has been discontinued, indicating a shift in their research and development strategy.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxQNjByejhEZHpjMDhtLWFvQWQtdXBtb0ZkbkFXbE5Ob3FwUFgxX3RQLURPRF91UlBJMEhiMnQ0N21RaV9Kc0dOVmd5eGphVDd6STNLMm5VSzNLajZnVllZNzhOSXFqYk9wTm91a1hRZXlQcGQ3U2VsWl8xX3d4QWNpWDY5amlCWmxjbDhqclZyY3NRanZPb3FwSzctNGlXRmZqdGRLRDA5Ylo3cTIwUXpIUkl1U0pHVzJSX21iVmpzTDZsWGFkVDNWV24xcjVhcWVNRkprZ3d6STNpbEkzZmhPNDNZckZnZ3FlYVkxbnBVdm9aNHV4TEVnaw?oc=5","date":"2026-03-23","type":"deal","source":"PR Newswire","summary":"GlycoNex Inc. and Nippon Kayaku Co., Ltd. Enter Collaboration to Advance Next-Generation ADC Candidate GNX201-ADC - PR Newswire","headline":"GlycoNex Inc. and Nippon Kayaku Co., Ltd. Enter Collaboration to Advance Next-Generation ADC Candidate GNX201-ADC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxNZlhhdGRYYWZ6YVBTUEtMYW9Hd3NuMms0UTFRSVQ2WjJva2syM2NfQ1UxcmhSUURVTWt6ekN4OE1OeURsWkdlN3N5RzhjTTZjM0NNMTZxMmNLM1hydDdETUlObVVJWXNQeUJzZzlhQjJjUHBVWFkzZVJ1T2lQeVJMSlc0Qlo2UUdJaW00dHNMZm5qYTNLM2MzMEJFZl9BZllGdjhUOExXZ0JoOTJLRWpJ?oc=5","date":"2026-03-23","type":"deal","source":"Contract Pharma","summary":"GlycoNex, Nippon Kayaku Partner to Advance Next-Gen ADC Candidate - Contract Pharma","headline":"GlycoNex, Nippon Kayaku Partner to Advance Next-Gen ADC Candidate","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxQX0FqTTZ5b2t0UXdmbldPQmMzZU15clBzekdaekhUM0dEdmdKaFM5YUVwckdPSWRPZHBkWWV4MHhMclhQaWVvNmdyQkhnZGV2TGhaSVcxWFFNc19TZ0RlREQ0aWFiU0xrZ0RpbHdpd0VXY0hrRUVxV0JyTHF0MC00M2xnSFg3eVI5eElUb3BsUDJyamVCSkdtLV80cEFEaWJmTUF4M3I2SVJTbXFnbmdmWmJRUXlQWFNjdnBuVDIwZTlFSE00TjFjV01WVF9JakhGYkJLYUZzY1VOaDN0WEFmclhna25ORFls?oc=5","date":"2025-12-08","type":"pipeline","source":"PR Newswire","summary":"GlycoNex Signs CDMO Service Agreement with Change Cure to Advance HMGB1-Targeted Antibody Program - PR Newswire","headline":"GlycoNex Signs CDMO Service Agreement with Change Cure to Advance HMGB1-Targeted Antibody Program","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxPcXNrR2hObmZrb1BvXzJCbVIxczBGTVdaMHRuZkZPcDRZazVCSlRDWHFlY2dhMzQxOEprX0FySW1Md0ZfdmcyNGs0b1I4UTNiM3YxMklnMVNmOFBhemFIbW5ObGRUWnpjb1RzSXREZHhZSDcyam5SOUFPd29za3lnbTIzRFF5ZFV5Y0FSOW44ME1GWXI4TnZZSjZKZ2VxWnFxZld1dVFFbEhTdkZfYVVuTm5kaDZZZmpRakhqUkRRdXZCdnRaZk5LQjVPcDU1SHpZWE95cmxnZzdTTGdWTW5sbjQwQjl2dDhEUHJjODdoaw?oc=5","date":"2025-10-29","type":"trial","source":"PR Newswire","summary":"GlycoNex Announces Last Patient Dosed in Phase 3 Trial of SPD8, a Denosumab Biosimilar for Osteoporosis - PR Newswire","headline":"GlycoNex Announces Last Patient Dosed in Phase 3 Trial of SPD8, a Denosumab Biosimilar for Osteoporosis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxQVmZkSkFmb0NtenpSUHpQVVZNbElCaUZERUEtQjlYd190VGIwOHVEQWtmNjJ4RHlyVWhZTkFxcHc5S1ZwV3o3eW43S2F0bGRpTUtQc1d0QklydzZBZ1ZRcUo3dTFVZF95LW5Ianh2cW5MYzJzVE9QUF80RGRHakdQYXNUbTNUOUdFanMwdW1NSXg5Wnlya1hsbTdtdzhZa1lPUXFVMmtiSXh3VEtUQnoyZE5GbXlJMjJpdUFIWVFvSFlZaFZkV1BtaVdmYlJsclR4eHc3YkpRVDlBd0lia1hFTkN4ZDJKcjRINDdQSy1JSjFCbzJHcDdEcw?oc=5","date":"2025-06-12","type":"trial","source":"PR Newswire","summary":"GlycoNex Announces Publication of Preclinical Study on GNX1021, a Novel Glycan-Targeted ADC for Gastric Cancer - PR Newswire","headline":"GlycoNex Announces Publication of Preclinical Study on GNX1021, a Novel Glycan-Targeted ADC for Gastric Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxPc0xCb3d5U1RNeE9ERVFQX1FORkptaGV6UUI0Vm9xNlVia1pJaGtmRVZDNnlIa3ZpTUhsQXMtYmdYOVh2LTF4MzhpOENtaEtUcHhfeWM1RHZmZnBqWkNDSlZIbmFfRHhzaGJ3bHdxckQ5Nkg5MGM2Ul9oNjlpN0FDSDZfMUk4a1o2UUwydUcyLWl4UE5fYWFha0tySFRlWnFVZEM1X3p4Q2k1b3V2amNHT3NleEQ?oc=5","date":"2025-01-06","type":"patent","source":"PR Newswire","summary":"GlycoNex Announces Licensing Agreement for SPD8 Biosimilar - PR Newswire","headline":"GlycoNex Announces Licensing Agreement for SPD8 Biosimilar","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxOTTA1OFEyNGluU2ZnRFdlZnhZb1ptYmRzWHM2enhxRk4yTU44SUFsanozYWt5SGdzYmxoc1VGUXNwR2F3Z0ZPRzRKVG9WS0ZEVDZlX3I4N3pENnFNbFFQUUFwNVo5OW9NWmkxd1VocnMzUWJ6N0JicVJPRVZYUm1TeTBiMl9ldnBoSzZ2ajEtZER5Y2JlRDFNY1g4RWFWQmk2ZGpFWF80OGFwSldZQWNjdE9pWTNELVNoTzlXdHR3SFZFRmpnYjNuMTluQldEYnBhMzdxNDhha2xyQWVnbFE?oc=5","date":"2024-12-17","type":"trial","source":"PR Newswire","summary":"GlycoNex Announces First Patient Dosed in Phase 3 Clinical Trial for Denosumab Biosimilar - PR Newswire","headline":"GlycoNex Announces First Patient Dosed in Phase 3 Clinical Trial for Denosumab Biosimilar","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxQZVRHQlp3XzJlT0Q4c3dJenJqOU00VGo0UEQ1S3prOFpKZUJZRmxMUVk0N1lkR3d4Y3dGM25ybzkzclNySl9zcTExaEYzN0RFS3JZRWFSRGJxeVExcnBmLUlWMFRudjIzcEhxV2JRR18tb1FGN3JVeG9kT29EU2VxNHZ3amZCZmVsdjJwVVotWkhUalJtd0xIR2dhS1pxZXZBQUZhdHExSzJ3NHF6d1JmaEhMNDFaeTNfcGlWcHR6T2d3ZTdld19PUnZsMmVpMnlLSUF0UXJuUmNIMlBqeGVoTGd1RnZKem54?oc=5","date":"2024-11-12","type":"trial","source":"PR Newswire","summary":"GlycoNex Announces Manufacturing Agreement with Sterling for GNX102-ADC Clinical Trial Production - PR Newswire","headline":"GlycoNex Announces Manufacturing Agreement with Sterling for GNX102-ADC Clinical Trial Production","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}